These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 30472602

  • 1. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C, Chen C, An Q, Yang T, Sang Z, Yang Y, Ju Y, Tong A, Luo Y.
    Eur J Med Chem; 2019 Jan 15; 162():543-554. PubMed ID: 30472602
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3.
    Fan D, Liu P, Li Z, He X, Zhang L, Jiang W, Ang W, Yang T.
    Bioorg Chem; 2024 Sep 15; 150():107565. PubMed ID: 38905884
    [Abstract] [Full Text] [Related]

  • 3. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H, Clamor C, Müller K.
    J Nat Prod; 2018 Jul 27; 81(7):1636-1644. PubMed ID: 30003778
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
    Zhou Q, Peng C, Du F, Zhou L, Shi Y, Du Y, Liu D, Sun W, Zhang M, Chen G.
    Eur J Med Chem; 2018 May 10; 151():39-50. PubMed ID: 29604543
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
    Feng KR, Wang F, Shi XW, Tan YX, Zhao JY, Zhang JW, Li QH, Lin GQ, Gao D, Tian P.
    Eur J Med Chem; 2020 Sep 01; 201():112428. PubMed ID: 32603980
    [Abstract] [Full Text] [Related]

  • 6. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM, Grothey A.
    Drugs; 2017 Jul 01; 77(10):1091-1103. PubMed ID: 28573435
    [Abstract] [Full Text] [Related]

  • 7. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X, Wei Y, Wei X.
    Cancer Lett; 2020 Oct 28; 491():146-161. PubMed ID: 32798587
    [Abstract] [Full Text] [Related]

  • 8. Identification of new shikonin derivatives as STAT3 inhibitors.
    Qiu HY, Fu JY, Yang MK, Han HW, Wang PF, Zhang YH, Lin HY, Tang CY, Qi JL, Yang RW, Wang XM, Zhu HL, Yang YH.
    Biochem Pharmacol; 2017 Dec 15; 146():74-86. PubMed ID: 29066190
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH, Määttä J, Linder A, Sterbova S, Ohlsson C, Damber JE, Widmark A, Persson E.
    Prostate; 2021 Jun 15; 81(8):452-462. PubMed ID: 33822400
    [Abstract] [Full Text] [Related]

  • 10. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
    Qiu HY, Zhu X, Luo YL, Lin HY, Tang CY, Qi JL, Pang YJ, Yang RW, Lu GH, Wang XM, Yang YH.
    Sci Rep; 2017 Jun 06; 7(1):2863. PubMed ID: 28588262
    [Abstract] [Full Text] [Related]

  • 11. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D.
    Recent Pat Anticancer Drug Discov; 2021 Jun 06; 16(3):350-362. PubMed ID: 33655847
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
    Li N, Ou J, Bao N, Chen C, Shi Z, Chen L, Sun J.
    Bioorg Chem; 2020 Nov 06; 104():104208. PubMed ID: 32919131
    [Abstract] [Full Text] [Related]

  • 13. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
    Hanafi M, Chen X, Neamati N.
    J Med Chem; 2021 Feb 11; 64(3):1626-1648. PubMed ID: 33506674
    [Abstract] [Full Text] [Related]

  • 14. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z, Wang H, Ren H, Sun Y, Chen X.
    Molecules; 2023 Jul 27; 28(15):. PubMed ID: 37570646
    [Abstract] [Full Text] [Related]

  • 15. Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer.
    Fan C, Lou S, Shen C, Liao J, Ni H, Chen S, Zhu Z, Hu X, Xie W, Zhao H, Cui S.
    J Med Chem; 2024 Sep 12; 67(17):15291-15310. PubMed ID: 39226127
    [Abstract] [Full Text] [Related]

  • 16. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D, Yu T, Dong N, Wang B, Sun F, Jiang D.
    J Exp Clin Cancer Res; 2019 Jul 05; 38(1):289. PubMed ID: 31277685
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
    Zuo D, Shogren KL, Zang J, Jewison DE, Waletzki BE, Miller AL, Okuno SH, Cai Z, Yaszemski MJ, Maran A.
    J Exp Clin Cancer Res; 2018 Oct 04; 37(1):244. PubMed ID: 30286779
    [Abstract] [Full Text] [Related]

  • 18. Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.
    Bhasin D, Etter JP, Chettiar SN, Mok M, Li PK.
    Bioorg Med Chem Lett; 2013 Dec 15; 23(24):6864-7. PubMed ID: 24176397
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
    Bose M, Sanders A, Handa A, Vora A, Cardona MR, Brouwer C, Mukherjee P.
    Sci Rep; 2024 Feb 07; 14(1):3178. PubMed ID: 38326371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.